Welcome to our dedicated page for AKTIS ONCOLOGY SEC filings (Ticker: AKTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to aggregate U.S. regulatory filings for Aktis Oncology, Inc. (Nasdaq: AKTS), a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors. While specific SEC filings are not listed in the provided information, a Nasdaq-listed issuer such as Aktis Oncology would typically use SEC reports to describe its business, pipeline, risks, and capital structure in more detail.
Annual and quarterly reports, such as Forms 10-K and 10-Q when available, generally provide narrative and financial disclosure about companies like Aktis Oncology. For a clinical-stage radiopharmaceutical company, these documents often include descriptions of its miniprotein radioconjugate platform, targeted tumor types, clinical development plans, and factors that could affect its research and development activities.
Registration statements, such as the Form S-1 that Aktis Oncology reports was declared effective in connection with its initial public offering, offer additional background on the company’s history, founding, and the structure of its capital raising transactions. Aktis Oncology has stated that its common stock began trading on the Nasdaq Global Select Market under the ticker AKTS following the effectiveness of its Form S-1.
On this filings page, Stock Titan’s tools can be used to review such documents when they are available from the SEC’s EDGAR system. AI-powered summaries are designed to highlight key sections of lengthy filings, such as business descriptions, risk factors related to clinical development and radiopharmaceutical safety, and disclosures about collaborations like the company’s strategic relationship with Eli Lilly and Company.
Users interested in AKTS can use this page to monitor new filings as they appear, compare successive disclosures, and better understand how Aktis Oncology presents its radiopharmaceutical platform, pipeline candidates, and single operating segment focused on research and development in official regulatory documents.
Aktis Oncology, Inc. is offering 17,650,000 shares of common stock in an initial public offering, with an expected price range of $16.00 to $18.00 per share and a 30‑day underwriters’ option for up to 2,647,500 additional shares. The company expects about $274.5 million in net proceeds at a $17.00 midpoint, and 52,522,279 shares of common stock outstanding after the deal. Aktis is a clinical-stage radiopharmaceutical company developing miniprotein-based drugs targeting solid tumors, led by Nectin‑4 candidate [225Ac]Ac‑AKY‑1189 in a Phase 1b trial and B7‑H3 program [225Ac]Ac‑AKY‑2519 nearing an IND filing. Eli Lilly has indicated interest in purchasing approximately $100.0 million of stock in the IPO and previously paid $60.0 million upfront plus an equity investment in a discovery collaboration with milestones up to $1.2 billion. Aktis reported net losses of $44.0 million in 2024 and $48.6 million for the nine months ended September 30, 2025, with an accumulated deficit of $141.4 million and $246.2 million in cash, cash equivalents and marketable securities, which it believes will fund operations into 2029.